| Literature DB >> 33489430 |
David W Barton1, Amit S Piple2, C Taylor Smith2, Sterling A Moskal3, Jonathan J Carmouche2,4.
Abstract
INTRODUCTION: A fracture liaison service (FLS) is a coordinated system of care that streamlines osteoporosis management in the orthopaedic setting and can serve as an effective form of secondary preventative care in these patients. The present work reviews the available evidence regarding the impact of fracture liaison services on clinical outcomes.Entities:
Keywords: DXA; FLS; bisphosphonate; fracture liaison service; fracture prevention; minimum trauma fracture; mortality; osteoporosis; quality improvement; systematic review
Year: 2021 PMID: 33489430 PMCID: PMC7809296 DOI: 10.1177/2151459320979978
Source DB: PubMed Journal: Geriatr Orthop Surg Rehabil ISSN: 2151-4585
PICO Search Criteria.
| Patient/ Population | Population (>49 years old) with minimal trauma fracture |
|---|---|
| Intervention | Type A Fracture Liaison Service |
| Comparison | No secondary fracture prevention program |
| Outcomes | Rates of BMD scanning, antiresorptive therapy prescribing, hospital readmission, new fractures, mortality |
Patient Outcomes Corresponding to Fracture Liaison Service Implementation in Studies Included in Meta-Analysis.
| Article | Time span (years) | Sample size, W/ FLS | Sample size, W/O FLS | Outcome | Results |
|---|---|---|---|---|---|
| Nakayama et al 2015 | 3 | 516 | 416 | Any Refracture | Cox HR 0.67, CI 0.47-0.95, p 0.025 |
| Major Refracture | COX HR 0.59, CI 0.39-0.9, p 0.013 | ||||
| Mortality | COX HR 1.17, p = 0.23 | ||||
| Ruggiero et al 2015 | 1 | 210 | 172 | DXA | Fisher, t-test- chi, Pre-FLS n = 24 (20.68%) vs Post-FLS n = 62 (43.66%), p < 0.0001 |
| Rx | Fisher, t-test- chi, Pre-FLS n = 17 (14.65%) vs Post-FLS n = 56 (39.43%). Increase 24.78%, p < 0.0001 | ||||
| Mortality | Fisher, t-test- chi, Pre-FLS n = 22 (12.7%) vs Post-FLS n = 33 (15.7%), p = 0.5011 | ||||
| Wallace et al 2011 | 2 | 42 | 46 | Rx | Fisher, t-test- chi, Without FLS 60.9%, with FLS 90.5%. Increase 29.6%, p < 0.001 |
| Huntjen et al 2011 | 1 | 1335 | 1920 | Refracture | Cox HR 0.65, 95% CI: 0.51-0.84, p = 0.001. Pre-FLS n = 191 (9.9%) vs Post-FLS n = 89 (6.7%). |
| Mortality | Cox HR 0.67, 95% CI: 0.55-0.81, p < 0.001. Pre-FLS n = 343 (17.9%) vs Post-FLS n = 155 (11.6%). | ||||
| Huntjen et al 2014 | 1, 2, 2 | 1412 | 1910 | Refracture | Cox HR: 0.84 05% CI: 0.64-1.10, p < 0.05 |
| Refracture | Cox HR: 0.44 95% CI: 0.25-0.79, p < 0.05 | ||||
| Mortality | Cox HR: 0.65 95% CI: 0.53-0.79, p < 0.05 | ||||
| Hawley et al 2016 | 2, 1, 30 Day | Total: 33,152 | Total: 33,152 | Refracture | Cox HR = 1.03 (CI: 0.85-1.26), p > 0.05 |
| Mortality | Cox HR = 0.84 (95% CI: 0.77-0.93) | ||||
| Mortality | Cox HR = 0.80 (95% CI: 0.71-0,91) | ||||
| Suarez et al 2017 | 1 | Total: 298 | Total: 298 | Mortality | Cox FLS HR 0.54, 95% CI: 0.292-0.997, p = 0.49. Pre-FLS 19.88% vs Post-FLS 10.95% |
| Murray et al 2005 (Post Prox Humeral Fx) | 0.5 | 170 | 80 | DXA | FLS(+) 70.6% vs FLS(−) 6% |
| Rx | FLS(+) 44.2% vs FLS(−)19% | ||||
| Murray et al 2005 (Post Hip Fx) | 0.5 | 194 | 64 | DXA | FLS(+) 19.5% vs FLS(−) 9.7% |
| Rx | FLS(+) 85% vs FLS(−) 26.9% | ||||
| Axelsson et al 2016 | 1 | 2616 | 2713 | DXA | Cox HR 7 (95% CI 6-8.1), p < 0.01. FLS(−) 7.6% vs FLS (+) 39.6% |
| Rx | Cox HR 2.8 (95% CI 2.5-3.2), p < 0.001. FLS(−) 12.6% vs FLS(+) 31.8% | ||||
| Refracture | Cox HR 0.95 (95% CI 0.76-1.03) p = 0.59. FLS(−) 8.4% vs FLS(+) 8.3%, p = 0.85 | ||||
| Mortality | Cox HR 0.87 (95% CI 0.76-1.03), p = 0.11. FLS (−) 13.3% vs FLS(+) 12.2%, p = 24 | ||||
| Suzuki et al 2016 | 1 | 588 | 191 | Rx | FLS(+) 39.5% vs FLS(−) 20.9% |
Figure 1.Improvement in DXA scanning rate with FLS implementation.
Figure 2.Improvement in antiresorptive pharmacotherapy prescribing rate with FLS implementation.